Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
TELA Bio, Inc. (NASDAQ:TELA) insider Ew Healthcare Partners Fund 2, acquired 5,050 shares of TELA Bio stock in a transaction dated Thursday, December 16th. The shares were acquired at an average price of $12.45 per share, with a total value of $62,872.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Ew Healthcare Partners Fund 2, also recently made the following trade(s): On Tuesday, December 14th, Ew Healthcare Partners Fund 2, acquired 10,000 shares of TELA Bio stock. The shares were acquired at an average price of $12.33 per share, with a total value of $123,300.00. On Friday, December 10th, Ew Healthcare Partners Fund 2, acquired 1,387 shares of TELA Bio stock. The shares were acquired at an average price of $12.49 per share, with a total value of $17,323.63. On Wednesday, December 8th, Ew Healthcare Partners Fund 2, acquired 1,425 shares of TELA Bio stock. The shares were acquired at an average price of $12.39 per share, with a total value of $17,655.75. On Monday, December 6th, Ew Healthcare Partners Fund 2, acquired 10,000 shares of TELA Bio stock. The shares were acquired at an average price of $12.39 per share, with a total value of $123,900.00. On Monday, November 22nd, Ew Healthcare Partners Fund 2, acquired 3,295 shares of TELA Bio stock. The shares were acquired at an average price of $12.49 per share, with a total value of $41,154.55. On Wednesday, November 17th, Ew Healthcare Partners Fund 2, acquired 1,000 shares of TELA Bio stock. The shares were acquired at an average price of $12.50 per share, with a total value of $12,500.00. On Wednesday, November 10th, Ew Healthcare Partners Fund 2, bought 1,000 shares of TELA Bio stock. The stock was purchased at an average cost of $12.50 per share, for a total transaction of $12,500.00. On Wednesday, October 27th, Ew Healthcare Partners Fund 2, bought 5,088 shares of TELA Bio stock. The stock was purchased at an average cost of $12.43 per share, for a total transaction of $63,243.84. On Wednesday, October 20th, Ew Healthcare Partners Fund 2, bought 2,090 shares of TELA Bio stock. The stock was purchased at an average cost of $12.42 per share, for a total transaction of $25,957.80. On Wednesday, October 13th, Ew Healthcare Partners Fund 2, bought 200 shares of TELA Bio stock. The stock was purchased at an average cost of $12.50 per share, for a total transaction of $2,500.00.
Shares of TELA stock traded down $0.13 on Friday, reaching $12.67. The stock had a trading volume of 11,789 shares, compared to its average volume of 30,002. The company has a quick ratio of 6.32, a current ratio of 6.99 and a debt-to-equity ratio of 1.13. The firm's 50-day moving average is $12.72 and its two-hundred day moving average is $13.56. The firm has a market capitalization of $183.77 million, a price-to-earnings ratio of -5.66 and a beta of 1.66. TELA Bio, Inc. has a 12 month low of $11.03 and a 12 month high of $18.00.
TELA Bio (NASDAQ:TELA) last released its quarterly earnings results on Wednesday, November 10th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.52) by ($0.05). The company had revenue of $7.65 million during the quarter, compared to the consensus estimate of $7.30 million. TELA Bio had a negative net margin of 121.27% and a negative return on equity of 84.60%. On average, sell-side analysts forecast that TELA Bio, Inc. will post -2.29 earnings per share for the current fiscal year.
Separately, Zacks Investment Research cut shares of TELA Bio from a "hold" rating to a "sell" rating in a report on Tuesday, November 16th.
A number of institutional investors have recently added to or reduced their stakes in TELA. Morgan Stanley raised its holdings in TELA Bio by 3,256.9% in the 2nd quarter. Morgan Stanley now owns 6,781 shares of the company's stock valued at $109,000 after acquiring an additional 6,579 shares during the period. Bank of America Corp DE raised its holdings in TELA Bio by 16.6% in the 2nd quarter. Bank of America Corp DE now owns 7,682 shares of the company's stock valued at $124,000 after acquiring an additional 1,093 shares during the period. Walleye Capital LLC bought a new position in TELA Bio in the 2nd quarter valued at about $189,000. Tibra Equities Europe Ltd bought a new position in TELA Bio in the 2nd quarter valued at about $208,000. Finally, Millennium Management LLC bought a new position in TELA Bio in the 1st quarter valued at about $266,000. 83.33% of the stock is currently owned by hedge funds and other institutional investors.
TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Recommended Story: Investing strategies using the yield curve
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider TELA Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.
While TELA Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Each market day you'll get a one-minute market summary to help you invest wisely.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information
© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.